David Potter, MD, PhD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Gilead
    Date added:
    08/03/2023
    Date updated:
    08/23/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    ImmunoMet Therapeutics
    Date added:
    08/23/2023
    Date updated:
    08/23/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Pfizer
    Date added:
    08/23/2023
    Date updated:
    08/23/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Nektar Therapeutics
    Date added:
    08/23/2023
    Date updated:
    08/23/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Takeda
    Date added:
    08/23/2023
    Date updated:
    08/23/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Seattle Genetics
    Date added:
    08/23/2023
    Date updated:
    08/23/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Innocrin Pharmaceuticals
    Date added:
    08/23/2023
    Date updated:
    08/23/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    AstraZeneca
    Date added:
    08/23/2023
    Date updated:
    08/23/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    AbbVie
    Date added:
    08/23/2023
    Date updated:
    08/23/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Gilead
    Date added:
    08/23/2023
    Date updated:
    08/23/2023

Pages

Return to Best of ASCO 2024, Minneapolis